- Home
- WINT vs TCRT Comparison
WINT vs TCRT Comparison
Compare WINT & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WINT
- TCRT
- Stock Information
- Founded
- WINT 1992
- TCRT 1998
- Country
- WINT United States
- TCRT United States
- Employees
- WINT N/A
- TCRT N/A
- Industry
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- TCRT Biotechnology: Pharmaceutical Preparations
- Sector
- WINT Health Care
- TCRT Health Care
- Exchange
- WINT Nasdaq
- TCRT Nasdaq
- Market Cap
- WINT 3.6M
- TCRT 3.8M
- IPO Year
- WINT 1995
- TCRT N/A
- Fundamental
- Price
- WINT $0.83
- TCRT $2.84
- Analyst Decision
- WINT Hold
- TCRT
- Analyst Count
- WINT 1
- TCRT 0
- Target Price
- WINT $350.00
- TCRT N/A
- AVG Volume (30 Days)
- WINT 224.2K
- TCRT 23.8K
- Earning Date
- WINT 05-16-2025
- TCRT 05-27-2025
- Dividend Yield
- WINT N/A
- TCRT N/A
- EPS Growth
- WINT N/A
- TCRT N/A
- EPS
- WINT N/A
- TCRT N/A
- Revenue
- WINT N/A
- TCRT $10,000.00
- Revenue This Year
- WINT N/A
- TCRT $5,680,500.00
- Revenue Next Year
- WINT N/A
- TCRT N/A
- P/E Ratio
- WINT N/A
- TCRT N/A
- Revenue Growth
- WINT N/A
- TCRT 100.00
- 52 Week Low
- WINT $1.01
- TCRT $1.31
- 52 Week High
- WINT $737.50
- TCRT $14.20
- Technical
- Relative Strength Index (RSI)
- WINT 29.36
- TCRT 55.73
- Support Level
- WINT $0.81
- TCRT $2.77
- Resistance Level
- WINT $0.95
- TCRT $2.95
- Average True Range (ATR)
- WINT 0.09
- TCRT 0.22
- MACD
- WINT 0.04
- TCRT -0.01
- Stochastic Oscillator
- WINT 6.14
- TCRT 78.85
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.